Blood Pressure J-Curve: Current Concepts

被引:0
作者
Maciej Banach
Wilbert S. Aronow
机构
[1] Medical University of Lodz,Department of Hypertension, Chair of Nephrology and Hypertension
[2] New York Medical College,Department of Medicine
[3] WAM University Hospital in Lodz,Department of Hypertension
[4] Medical University of Lodz,undefined
来源
Current Hypertension Reports | 2012年 / 14卷
关键词
Blood pressure; J-curve; High-risk populations; Cardiovascular risk; Diabetes; Coronary artery disease; CAD; Elderly; Left ventricle hypertrophy; LVH; Hypertension; Hypotensive therapy; Antihypertensive treatment;
D O I
暂无
中图分类号
学科分类号
摘要
The blood pressure (BP) J-curve debate started in 1979, and we still cannot definitively answer all the questions. However, available studies of antihypertensive treatment provide strong evidence for J-shaped relationships between both diastolic and systolic BP and main outcomes in the general population of hypertensive patients, as well as in high-risk populations, including subjects with coronary artery disease, diabetes mellitus, left ventricular hypertrophy, and elderly patients. However, further studies are still necessary in order to clarify this issue. This is connected to the fact that most available studies were observational, and randomized trials did not have or lost their statistical power and were inconclusive. Perhaps only the Systolic Blood Pressure Intervention Trial (SPRINT) and Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (ESH-CHL-SHOT) will be able to finally answer all the questions. According to the current state of knowledge, it seems reasonable to suggest lowering BP to values within the 130–139/80–85 mmHg range, possibly close to the lower values in this range, in all hypertensive patients and to be very careful with further BP level reductions, especially in high-risk hypertensive patients.
引用
收藏
页码:556 / 566
页数:10
相关论文
共 462 条
[1]  
Lloyd-Jones D(2009)Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 e21-e181
[2]  
Adams R(2006)Worldwide epidemic of hypertension Can J Cardiol 22 553-555
[3]  
Carnethon M(2011)The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe Curr Cardiovasc Risk Rep 5 174-179
[4]  
Chockalingam A(2011)Lipids, blood pressure, kidney—what was new in 2011? Arch Med Sci 7 1055-1066
[5]  
Campbell NR(2009)Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2121-2158
[6]  
Fodor JG(2010)Editorial. Controversies in hypertension treatment Curr Vasc Pharmacol 8 731-732
[7]  
Bielecka-Dabrowa A(2006)Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144 884-893
[8]  
Aronow WS(2012)Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes Curr Cardiol Rep 14 89-96
[9]  
Rysz J(2011)What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother 12 1835-1844
[10]  
Banach M(2012)An update on biomarkers of heart failure in hypertensive patients J Hypertens 30 1681-1689